Search

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

EHA has a policy on life events and eligibility. If you're submitting a Mentorship Program application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

Jun 13 2014 Posted in Press releases

Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

EHA-AHA-GBMA Mini Hematology Tutorial

For the first time EHA is collaborating simultaneously with the Armenian Hematology Association (AHA) and Georgian Association For Blood and Bone Marrow Transplantation (GBMTA) in a virtual Mini Hematology Tutorial.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.